A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

Summary

This study is a phase I clinical study of the safety, tolerability, and pharmacokinetics of BAT4406F injection in patients with neuromyelitis optica spectrum disorders.

Timeline

Start

2020-09-01

Primary completion

2023-03-13

Completion

2023-12-25

Publications

• Yu H, Chen Y, Qi Y, Yang H, Cao G, Yang W, Li S, Yang X, Wang H, Zhang J, Chen X. First-in-Human Study of BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody in Patients With Neuromyelitis Optica Spectrum Disorders. CNS Neurosci Ther. 2024 Nov;30(11):e70126. doi: 10.1111/cns.70126.

Drugs

Indications